W. Roger Rush
Corporate Officer/Principal bei INHIBIKASE THERAPEUTICS, INC.
Profil
W.
Roger Rush is currently the Head-Preclinical Research at Inhibikase Therapeutics, Inc. and Principal at Allon Preclinical Consulting LLC.
Previously, he worked as the Vice President-Preclinical Development at Idenix Pharmaceuticals LLC from 2012 to 2014.
He also held positions as Principal at Critical Therapeutics, Inc., Roche Palo Alto LLC, and Scotia Pharmaceuticals Ltd.
Additionally, he was the Vice President-Preclinical Development at Seaside Therapeutics LLC.
Rush received his undergraduate and doctorate degrees from the University of Surrey in 1976 and 1979, respectively.
Aktive Positionen von W. Roger Rush
| Unternehmen | Position | Beginn |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2015 |
| Allon Preclinical Consulting LLC | Corporate Officer/Principal | 01.02.2015 |
Ehemalige bekannte Positionen von W. Roger Rush
| Unternehmen | Position | Ende |
|---|---|---|
| IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01.12.2014 |
Scotia Pharmaceuticals Ltd.
 Scotia Pharmaceuticals Ltd. Medical DistributorsDistribution Services Scotia Pharmaceuticals Ltd. engages in a pharmaceutical company. The company was founded on November 2, 1978 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
| Critical Therapeutics, Inc. | Corporate Officer/Principal | - |
Roche Palo Alto LLC
 Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | - |
Seaside Therapeutics LLC
 Seaside Therapeutics LLC Medical DistributorsDistribution Services Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von W. Roger Rush
| University of Surrey | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Seaside Therapeutics LLC
Seaside Therapeutics LLC Medical DistributorsDistribution Services Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA. | Distribution Services |
| Critical Therapeutics, Inc. | Health Technology |
Roche Palo Alto LLC
Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA. | Health Technology |
Scotia Pharmaceuticals Ltd.
Scotia Pharmaceuticals Ltd. Medical DistributorsDistribution Services Scotia Pharmaceuticals Ltd. engages in a pharmaceutical company. The company was founded on November 2, 1978 and is headquartered in London, the United Kingdom. | Distribution Services |
| Allon Preclinical Consulting LLC | |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
